Biotechnology - Oncology

Filter

Current filters:

Oncology

Popular Filters

1 to 25 of 629 results

Janssen partners with MacroGenics in up to $625 million deal

Janssen partners with MacroGenics in up to $625 million deal

23-12-2014

Shares of US biotech firm MacroGenics rocketed 11.7% to a 10-month high of $38.58 yesterday, on the news…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingMacroGenicsMergers & AcquisitionsMGD011Oncology

Roche shares fall sharply on disappointing Ph III MARIANNE study

Roche shares fall sharply on disappointing Ph III MARIANNE study

22-12-2014

Swiss pharma major Roche saw its shares plunge 6.4% to 270.40 Swiss francs on Friday following release…

BiotechnologyGenentechHerceptinKadcylaOncologyPerjetaRoche

Gilead and Ono enter into a licensing agreement for ONO-4059

Gilead and Ono enter into a licensing agreement for ONO-4059

19-12-2014

Japanese pharma company Ono Pharmaceutical and US biotech major Gilead Sciences have entered into a licensing…

BiotechnologyGilead SciencesLicensingOncologyOno PharmaceuticalONO-4059Research

Sorrento and Conkwest join forces on cancer immunotherapies development

Sorrento and Conkwest join forces on cancer immunotherapies development

19-12-2014

US cancer drug developer Sorrento Therapeutic and privately-held Conkwest have entered into a definitive…

BiotechnologyConkwestFinancialNeukoplastOncologyResearchSorrento Therapeutics

Merck & Co in up to $375 million deal to acquire OncoEthix

Merck & Co in up to $375 million deal to acquire OncoEthix

19-12-2014

US pharma giant Merck & Co said yesterday that it has acquired, through a subsidiary, Swiss-based privately…

BiotechnologyMerck & CoMergers & AcquisitionsOncoEthixOncologyOTX015

Roche to acquire Austrian next-generation antibody firm Dutalys

Roche to acquire Austrian next-generation antibody firm Dutalys

19-12-2014

Swiss pharma giant Roche has agreed to acquire Dutalys, a privately held biotechnology company based…

BiotechnologyDutalysDutaMabMergers & AcquisitionsOncologyRoche

Amgen reveals Blincyto price as $178,000 per course

Amgen reveals Blincyto price as $178,000 per course

18-12-2014

USA-based Amgen has revealed its intended pricing for its immunotherapy Blincyto (blinatumomab), which…

AmgenBiotechnologyBlincytoOncologyPricingUSA

Curie-Cancer renews research partnership with GamaMabs Pharma for ovarian cancer drug

Curie-Cancer renews research partnership with GamaMabs Pharma for ovarian cancer drug

16-12-2014

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities,…

BiotechnologyFranceGamaMabs PharmaOncologyResearch

Anthera Pharma licenses Japan rights for blisibimod to Zenyaku Kogyo

Anthera Pharma licenses Japan rights for blisibimod to Zenyaku Kogyo

16-12-2014

US development-stage biophama company Anthera Pharmaceuticals has entered into an exclusive licensing…

AmgenAnthera PharmaceuticalsBiotechnologyblisibimodJapanLicensingOncologyZenyaku Kogyo

Astellas Venture Management invests in Crescendo's Humabody antibody fragment project

Astellas Venture Management invests in Crescendo's Humabody antibody fragment project

16-12-2014

UK-based antibody therapeutics specialist Crescendo Biologics has received another equity investment…

BiotechnologyBusiness FinanceCrescendo BiologicsOncologyUK

Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

15-12-2014

Oncology specialist Sorrento Therapeutics has entered into a binding agreement with medical technology…

BiotechnologyLicensingOncologyResearchSorrento TherapeuticsUSA

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

Genentech files NDA for cobimetinib with Zelboraf in advanced melanoma

15-12-2014

Genentech, the US biotech subsidiary of Swiss Pharma major Roche Group, has submitted a New Drug Application…

BiotechnologycobimetinibExelixisGenentechOncologyRegulationRocheUSAZelboraf

Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics

Gilead appoints Philippe Bishop as senior vice president of hematology and oncology therapeutics

15-12-2014

US biotech major Gilead Sciences has appointed Philippe Bishop as senior vice president of hematology…

BiotechnologyBoardroomGilead SciencesHematologyOncologyUSA

Ignyta and Nerviano amend license accord on entrectinib

Ignyta and Nerviano amend license accord on entrectinib

15-12-2014

US oncology focused biotech firm Ignyta has agreed to an amendment to its license agreement with Italy’s…

BiotechnologyentrectinibIgnytaLicensingNerviano Medical SciencesOncologyRXDX-101

NetScientific invests in PDS Biotechnology

NetScientific invests in PDS Biotechnology

15-12-2014

UK-based life sciences investor NetScientific has made an undisclosed investment in privately-held US…

Antibiotics and Infectious diseasesBiotechnologyMergers & AcquisitionsNetScientificOncologyPDS BiotechnologyUK

Calithera gains exclusive, global license to Mars Symbioscience's arginase inhibitors

09-12-2014

Calithera Biosciences has signed an exclusive global license agreement with Mars Symbioscience, a division…

BiotechnologyCalithera BiosciencesGlobalLicensingMars SymbioscienceOncology

FDA approves new indication for Amgen's Xgeva

FDA approves new indication for Amgen's Xgeva

08-12-2014

USA-based Amgen says the US Food and Drug Administration has approved a new indication for Xgeva (denosumab),…

AmgenBiotechnologyOncologyRare diseasesRegulationUSAXgeva

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

08-12-2014

Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyResearchSandoz

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

08-12-2014

USA-based Amgen and its subsidiary Onyx Pharmaceuticals announced the results of the Phase III ASPIRE…

AmgenBiotechnologyDexamethasoneKyprolisOncologyOnyx PharmaceuticalsResearchRevlimid

US FDA approves new indication for Incyte’s Jakafi

US FDA approves new indication for Incyte’s Jakafi

05-12-2014

The US Food and Drug Administration yesterday approved a new use for Incyte Corp’s Jakafi (ruxolitinib)…

BiotechnologyIncyteJakafiOncologyRegulationUSA

Array BioPharma to regain global rights to binimetinib from Novartis

04-12-2014

Shares of US biotech firm Array BioPharma leapt 22.8% to $4.80 in after-hours trading on Wednesday, after…

Array BioPharmabinimetinibBiotechnologyGlobalLicensingNovartisOncology

US FDA grants earlier approval for Amgen’s Blincyto for rare form of lymphoblastic leukemia

US FDA grants earlier approval for Amgen’s Blincyto for rare form of lymphoblastic leukemia

04-12-2014

Ahead of the anticipated decision date, the US Food and Drug Administration yesterday approved Blincyto…

AmgenBiotechnologyblinatumomabBlincytoOncologyRegulationUSA

Puma shares plummet as it delays NDA filing

Puma shares plummet as it delays NDA filing

03-12-2014

Puma Biotechnology will delay the filing of its New Drug Application (NDA) for the approval of PB272…

BiotechnologyneratinibOncologyPuma BiotechnologyRegulationUSA

1 to 25 of 629 results

Back to top